In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Givaudan

This article was originally published in The Rose Sheet

Executive Summary

First quarter fragrance sales decline 1.8% in Swiss Francs, or .3% in local currencies to $214.5 mil. (1 CHF=$0.77) due to discontinued sales of commodity ingredients, firm reports. Fine fragrances, however, experienced double-digit growth in local currencies driven by the launches of several prestige fragrances. Total sales in the quarter grew 2.4% in Swiss Francs, or 4.1% in local currencies, to $540.5 mil. Givaudan will continue to focus on developing proprietary fragrance ingredients this year, the company said during its annual investor meeting April 8. Among the exclusive ingredients Givaudan plans to launch is Toscanol, a replacement for Estragole, which has been found to be a naturally occurring genotoxic carcinogen. The company also will introduce Javanol, a sandalwood odorant at the World Perfumery Congress June 1-5 in Cannes, France, according to Givaudan Head of Fragrance Chemistry Markus Gautschi...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel